At the time of writing, a total of 10 PD-1/PD-L1 monoclonal antibodies are approved by regulatory authorities either as monotherapy or in combination across different lines of treatment for 19 different types of cancer, including a tissue-agnostic indication (Supplemental Table 1). This evidence concerns the gene PDCD1 and cancer.